![](/img/cover-not-exists.png)
A phase I dose-reduction study of apatinib combined with pemetrexed and carboplatin in untreated EGFR and ALK negative stage IV non-squamous NSCLC
Huang, Meijuan, Gong, Youling, Zhu, Jiang, Qin, Yi, Peng, Feng, Ren, Li, Ding, Zhenyu, Liu, Yongmei, Cai, Chengzhi, Wang, Yongsheng, Lu, YouLanguage:
english
Journal:
Investigational New Drugs
DOI:
10.1007/s10637-019-00811-6
Date:
June, 2019
File:
PDF, 414 KB
english, 2019